END 7-OH Act
Summary
The END 7-OH Act (HR8000) is an early-stage bill that would schedule synthetic 7-hydroxymitragynine as a Schedule I controlled substance, explicitly exempting natural kratom. No publicly traded companies are directly exposed to this niche regulation, and the bill faces a long legislative path with low near-term probability of passage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The bill is in early stage with low probability of passage.
- 2.No publicly traded companies are directly affected.
- 3.The bill explicitly exempts natural kratom, limiting its scope.
Market Implications
No market implications are expected from this bill. The energy sector data provided (e.g., $COP, $XOM) is unrelated, and no other sectors are affected. The bill's narrow scope and early stage mean no actionable investment signal.
Full Analysis
The END 7-OH Act, introduced by Rep. Bilirakis (R-FL-12) on March 19, 2026, targets synthetic 7-hydroxymitragynine, a compound sometimes produced synthetically and found in some kratom extracts. The bill specifically exempts the naturally occurring compound in the kratom plant (Mitragyna speciosa), so it does not ban natural kratom. The legislation is currently in the earliest stage: referred to the House Energy and Commerce and Judiciary Committees with no further action. The bill authorizes no funding—it is a scheduling amendment under the Controlled Substances Act, which is a regulatory action, not a spending bill. The legislative path requires committee consideration, House passage, Senate passage, and presidential approval, which is highly uncertain given the 119th Congress's track record on niche drug scheduling bills. There are no publicly traded companies that are pure-play manufacturers of synthetic 7-OH, and the major kratom industry players are private. The bill's impact on broader healthcare or supplement sectors is negligible. Investors should view this as a procedural bill with no near-term market consequences.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →